Srpanj 2022: On July 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and ACT Therapeutics (Seogkyoung-Kong, CEO), developing a next-generation chimeric antigen receptor (CAR)-T cell therapy platform targeting solid cancer, announced that they had entered into a strategic partnership MOU concerning the development of a new CAR-T cell therapies. The MOU was in regard to the development of new CAR-T cell therapies. Through the use of this memorandum of understanding (MOU), GenScript ProBio and ACT Therapeutics have come to an agreement to further their collaboration in the field of cell therapy.
ACT Therapeutics i GenScript ProBio u procesu su potpisivanja ugovora za razvoj i proizvodnju plazmida i virusnih vektora za prvu liniju napredne CAR-T platforme ACT Therapeutics (ACT platforma), koja će također biti zadužena za proizvodnju sirovina za ACT Therapeutics'ove sljedeće projekte. Ugovor će pokriti proizvodnju plazmida i vektora virusa za prvu liniju napredne CAR-T platforme tvrtke ACT Therapeutics.
Kao rezultat ovog sporazuma, GenScript ProBio je podignut u status globalnog partnera koji može podržati ACT platforme za ACT terapiju.
ACT platforma je nova generacija tehnologije stanične i genske terapije koja cilja na antigene raka umetanjem gena dizajniranih za ciljanje tih antigena u imunološke stanice. Ti se geni dostavljaju u imunološke stanice korištenjem virusnih vektora. GenScript ProBio posjeduje visokokvalitetni razvoj procesa vektora virusa i platformu usluge na jednom mjestu za GMP proizvodnju, a oboje je neophodno za razvoj stanične i genske terapije.
ACT Therapeutics’ ACT platform is an advanced CAR-T technology that has a next-generation structure that goes beyond the second-generation CAR-T cell therapy and targets existing rak krvi. This is accomplished by overcoming the immune suppression microenvironment of solid cancer and activating the immune cells that are surrounding the cancer. Several studies have also used animals to test the ACT platform to see how well it works and if it is safe. These studies have also confirmed that the platform can be used to treat solid cancer while staying in the immunosuppressive environment of that cancer. Additionally, it complements the shortcomings of the existing second-generation CAR-T, which makes it a competitive technology for the treatment of solid cancer.
ACT Therapeutics is a Korean bio venture company that has received initial investment through DAYLI Partners, Korea’s leading bio and healthcare venture capital, since its establishment in 2020, and has been recognized for its technology such as receiving pre-series A investment in Samho Green Investment. DAYLI Partners is Korea’s leading bio and healthcare venture capital since its establishment in 2020. At the moment, investment consultations are being held with various securities firms and venture capital companies in order to entice Series A investment.
Brian H. Min, CEO of GenScript ProBio, said, “We are very happy to cooperate with ACT therapeutics in strategic partnership, and we are looking forward to support ACT Therapeutics’ ACT platform as a global partner through our accumulated technology.”
Seogkyoung-Kong, glavni izvršni direktor ACT Therapeuticsa, rekao je: “Dovršili smo pripreme za globalnu pojavu ACT platforme kroz strateško partnerstvo s GenScript ProBio. Ubrzat ćemo razvoj tretmana koji ciljaju otporne i teško izliječive solidne karcinome.”
O GenScript ProBio
GenScript ProBio is a subsidiary of GenScript Biotech Corporation, proactively providing end-to-end CDMO service from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in cell and gene therapy (CGT), vaccine discovery, biologics discovery and antibody protein drug development to accelerate drug development for customers. GenScript ProBio has established companies in the United States, the Netherlands, South Korea, Shanghai, Hong Kong, Nanjing and other places to serve global customers, and supported customers in the United States, Europe, Asia Pacific and other regions to obtain more than 30 IND approvals.
U skladu s misijom "Inovacija kroz suradnju", GenScript ProBio je predan pomaganju korisnicima da skrate vremenski rok za razvoj bioloških lijekova od otkrića do komercijalizacije, značajno smanjujući troškove istraživanja i razvoja i gradeći zdraviju budućnost.
